Synaptic Systems - Abeta-pE3

Cat. No.: 218 011

Amount: 100 µg

Price: $415.00

Cat. No. 218 011	100 µg purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H₂O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications	WB: 1 : 1000 (see remarks) gallery IP: not tested yet ICC: not tested yet IHC: 1 : 400 (see remarks) gallery IHC-P: 1 : 100 gallery ELISA: yes (see remarks) Western blot (WB); separation of proteins by PAGE and subsequent transfer to a membrane. Detection of target molecules is carried out with antibodies. Some antibodies require special sample preparation steps. For details, please refer to the “Remarks” section. Immunoprecipitation (IP); Immunoisolation or pulldown of a target molecule using an antibody. For details and product specific hints, please refer to the ”Remarks” section. Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section. Immunohistochemistry (IHC) on 4% PFA perfusion fixed tissue with 24h PFA post fixation. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Some antibodies require special fixation methods or antigen retrieval steps. For details, please refer to the ”Remarks” section. Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Enzyme-linked immunosorbent assay (ELISA); a frequently employed method to quantify target-molecules in solution. The detection of some proteins requires special solubilization steps. For further information, please refer to the „Remarks“ section.
Clone	2-48
Subtype	IgG1 (κ light chain)
Immunogen	Synthetic peptide corresponding to AA 3 to 7 from human Abeta-pE3 (UniProt Id: P05067)
Reactivity	Reacts with: human (P05067), rat (P08592), mouse (P12023), monkey. Other species not tested yet.
Specificity	Specific for Abeta-pE3.
Remarks	WB: Detects purified Abeta pE3. Complex samples like brain extracts still have to be tested. Boil membrane after blotting for 3min. IHC: Antigen retrieval with formic acid is required. ELISA: The biotinylated antibody (218 011BT) is suitable as detector antibody for sandwich-ELISA with cat. no. 218 111 or 218 511 as capture antibody.
Data sheet	218_011.pdf

References for Abeta-pE3 - 218 011

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.
Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, et al.
Journal of neural transmission (Vienna, Austria : 1996) (2010) 1171: 85-96. 218 011 WB, IHC-P; tested species: human

Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.
Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA
Acta neuropathologica (2009) 1184: 487-96. 218 011 WB

Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.
Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth HU, Blennow K, Wirths O, Bayer TA
The Journal of biological chemistry (2012) 28711: 8154-62. 218 011 IP

Porphyromonas gingivalis Infection Induces Amyloid-β Accumulation in Monocytes/Macrophages.
Nie R, Wu Z, Ni J, Zeng F, Yu W, Zhang Y, Kadowaki T, Kashiwazaki H, Teeling JL, Zhou Y
Journal of Alzheimer's disease : JAD (2019) : . 218 011 IHC; tested species: human,mouse

Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice.
Wang X, Wang L, Yu X, Li Y, Liu Z, Zou Y, Zheng Y, He Z, Wu H
International immunopharmacology (2019) 75: 105770. 218 011 IHC; tested species: mouse

Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.
Hartlage-Rübsamen M, Waniek A, Meissner J, Morawski M, Schilling S, Jäger C, Kleinschmidt M, Cynis H, Kehlen A, Arendt T, Demuth HU, et al.
Acta neuropathologica (2015) 1294: 565-83. 218 011 IHC

Identification of thyrotropin-releasing hormone as hippocampal glutaminyl cyclase substrate in neurons and reactive astrocytes.
Waniek A, Hartlage-Rübsamen M, Höfling C, Kehlen A, Schilling S, Demuth HU, Roßner S
Biochimica et biophysica acta (2015) 18521: 146-55. 218 011 IHC

Detection and Quantification of β-Amyloid, Pyroglutamyl Aβ, and Tau in Aged Canines.
Schmidt F, Boltze J, Jäger C, Hofmann S, Willems N, Seeger J, Härtig W, Stolzing A
Journal of neuropathology and experimental neurology (2015) 749: 912-23. 218 011 IHC

Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
Morawski M, Schilling S, Kreuzberger M, Waniek A, Jäger C, Koch B, Cynis H, Kehlen A, Arendt T, Hartlage-Rübsamen M, Demuth HU, et al.
Journal of Alzheimer's disease : JAD (2014) 392: 385-400. 218 011 IHC; tested species: human

The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ.
Kalimo H, Lalowski M, Bogdanovic N, Philipson O, Bird TD, Nochlin D, Schellenberg GD, Brundin R, Olofsson T, Soliymani R, Baumann M, et al.
Acta neuropathologica communications (2013) 1: 60. 218 011 IHC; tested species: human

Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer's disease neuropathology.
Morawski M, Brückner G, Jäger C, Seeger G, Matthews RT, Arendt T
Brain pathology (Zurich, Switzerland) (2012) 224: 547-61. 218 011 IHC; tested species: human

Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
Hartlage-Rübsamen M, Morawski M, Waniek A, Jäger C, Zeitschel U, Koch B, Cynis H, Schilling S, Schliebs R, Demuth HU, Rossner S, et al.
Acta neuropathologica (2011) 1216: 705-19. 218 011 IHC

Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice.
Härtig W, Goldhammer S, Bauer U, Wegner F, Wirths O, Bayer TA, Grosche J
Journal of chemical neuroanatomy (2010) 401: 82-92. 218 011 IHC

Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
Morawski M, Hartlage-Rübsamen M, Jäger C, Waniek A, Schilling S, Schwab C, McGeer PL, Arendt T, Demuth HU, Rossner S
Acta neuropathologica (2010) 1202: 195-207. 218 011 IHC; tested species: human

The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease.
Murray CE, Gami-Patel P, Gkanatsiou E, Brinkmalm G, Portelius E, Wirths O, Heywood W, Blennow K, Ghiso J, Holton JL, Mills K, et al.
Acta neuropathologica communications (2018) 61: 62. 218 011 IHC-P; tested species: human

I716F AβPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-β and α-synucleinopathy with Lewy bodies.
Sieczkowski E, Milenkovic I, Venkataramani V, Giera R, Ströbel T, Höftberger R, Liberski PP, Auff E, Wirths O, Bayer TA, Kovacs GG, et al.
Journal of Alzheimer's disease : JAD (2015) 441: 103-14. 218 011 IHC-P; tested species: human

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease.
Bayer TA, Wirths O
Acta neuropathologica (2014) 1276: 787-801. 218 011 IHC-P; tested species: human

Oligomeric pyroglutamate amyloid-β is present in microglia and a subfraction of vessels in patients with Alzheimer's disease: implications for immunotherapy.
Wirths O, Hillmann A, Pradier L, Härtig W, Bayer TA
Journal of Alzheimer's disease : JAD (2013) 354: 741-9. 218 011 IHC-P; tested species: human

Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease.
Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O
Neurobiology of aging (2012) 331: 196.e29-40. 218 011 IHC-P; tested species: human

Cat. No.: 218 011

Amount: 100 µg

Price: $415.00

IHC

IHC-P

Background

Amyloid deposits, also called plaques, of Alzheimer's patients consist of several protein components like the amyloid beta-peptides (Abeta, Aβ) 1-40/42 and additional C- and N-terminally truncated and modified fragments. Very abundant are the isoaspartate (isoAsp)-Abeta and pyroglutamyl (pGlu)-Abeta peptides. The latter are formed by cyclization of the N-terminal glutamate at position 3 or 11 catalyzed by glutaminyl cyclase (QC) resulting in very amyloidogenic and neurotxic variants of Abeta; Abeta-pE3 and Abeta pE11.
In contrast to extracellular plaques that do not perfectly correlate with Alzheimer´s disease intraneuronal Abeta accumulation and vascular Abeta deposits have gained more and more evidence to be among the crucial factors responsible for progressive neuron loss.

1 ) Sullivan CP et al., Neurosci. Lett. (2011)
2 ) Perez-Garmendia R et al., J. Neuroimmunol. (2010)
3 ) Schilling S et al., Nat. Med. (2008)
4 ) Hook V et al., Biol. Chem. (2008)
5 ) Böhme L et al., Biol. Chem. (2008)
6 ) Schilling S et al., J. Neurochem. (2008)
7 ) Wiltfang J et al., J. Biol. Chem. (2001)
8 ) Wood SJ et al., J. Mol. Biol. (1996)
9 ) Kuo YM et al., J. Biol. Chem. (1996)

Protocols

IHC

IHC-P

ELISA

Standard protocol

Other products for this target

Abeta-pE3 antibody - 218 011

References for Abeta-pE3 - 218 011